KemPharm announces FDA approval of Azstarys (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), a new once daily treatment for ADHD

KemPharm

2 March 2021 - KemPharm today announced that the U.S. FDA has approved the new drug application for Azstarys (formerly referred to as KP415), a once daily product for the treatment of attention deficit hyperactivity disorder in patients age six years and older. 

Azstarys consists of serdexmethylphenidate, KemPharm’s pro-drug of d-methylphenidate, co-formulated with immediate release d-methylphenidate.

Read KemPharm press release

Michael Wonder

Posted by:

Michael Wonder